Now showing items 1-12 of 12

    • The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. 

      Heller, G; Fizazi, K; McCormack, R; Molina, A; MacLean, D; Webb, IJ; Saad, F; de Bono, JS; Scher, HI (2017-04)
      Purpose: Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease for which better prognostic models for survival are needed. We examined the added value of circulating tumor cell (CTC) enumeration ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      BACKGROUND:Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with ...
    • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. 

      Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandalà, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM (2017-11)
      BACKGROUND:Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ...
    • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. 

      Long, GV; Flaherty, KT; Stroyakovskiy, D; Gogas, H; Levchenko, E; de Braud, F; Larkin, J; Garbe, C; Jouary, T; Hauschild, A; Chiarion-Sileni, V; Lebbe, C; Mandalà, M; Millward, M; Arance, A; Bondarenko, I; Haanen, JBAG; Hansson, J; Utikal, J; Ferraresi, V; Mohr, P; Probachai, V; Schadendorf, D; Nathan, P; Robert, C; Ribas, A; Davies, MA; Lane, SR; Legos, JJ; Mookerjee, B; Grob, J-J (2017-07)
      Background:Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF ...
    • A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. 

      Mateo, J; Olmos, D; Dumez, H; Poondru, S; Samberg, NL; Barr, S; Van Tornout, JM; Jie, F; Sandhu, S; Tan, DS; Moreno, V; LoRusso, PM; Kaye, SB; Schöffski, P (2016-04)
      The kinase activity of mTOR involves 2 multiprotein complexes, (mTORC1-mTORC2). Targeting mTORC1 with rapalogues induces compensatory feedback loops resulting in AKT/ERK activation, which may be abrogated by mTORC2 inhibition. ...
    • A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

      Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; Kwak, EL; Macarulla Mercadé, T; Geuna, E; Jose de Miguel-Luken, M; Patel, C; Kuida, K; Sankoh, S; Westin, EH; Zohren, F; Shou, Y; Tabernero, J (2017-09)
      Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid ...
    • A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors. 

      Mateo, J; Ganji, G; Lemech, C; Burris, HA; Han, S-W; Swales, K; Decordova, S; DeYoung, MP; Smith, DA; Kalyana-Sundaram, S; Wu, J; Motwani, M; Kumar, R; Tolson, JM; Rha, SY; Chung, HC; Eder, JP; Sharma, S; Bang, Y-J; Infante, JR; Yan, L; de Bono, JS; Arkenau, H-T (2017-10)
      Background: The PI3K/protein kinase B (AKT) pathway is commonly activated in several tumor types. Selective targeting of p110β could result in successful pathway inhibition while avoiding the on- and off-target effects of ...
    • Implementing the EffTox dose-finding design in the Matchpoint trial. 

      Brock, K; Billingham, L; Copland, M; Siddique, S; Sirovica, M; Yap, C (2017-07-20)
      The Matchpoint trial aims to identify the optimal dose of ponatinib to give with conventional chemotherapy consisting of fludarabine, cytarabine and idarubicin to chronic myeloid leukaemia patients in blastic transformation ...
    • Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. 

      Vaughan, L; Clarke, PA; Barker, K; Chanthery, Y; Gustafson, CW; Tucker, E; Renshaw, J; Raynaud, F; Li, X; Burke, R; Jamin, Y; Robinson, SP; Pearson, A; Maira, M; Weiss, WA; Workman, P; Chesler, L (2016-09)
      MYC oncoproteins deliver a potent oncogenic stimulus in several human cancers, making them major targets for drug development, but efforts to deliver clinically practical therapeutics have not yet been realized. In childhood ...
    • International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. 

      Terpos, E; Morgan, G; Dimopoulos, MA; Drake, MT; Lentzsch, S; Raje, N; Sezer, O; García-Sanz, R; Shimizu, K; Turesson, I; Reiman, T; Jurczyszyn, A; Merlini, G; Spencer, A; Leleu, X; Cavo, M; Munshi, N; Rajkumar, SV; Durie, BGM; Roodman, GD (2013-06)
      The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease.An interdisciplinary panel of clinical experts on MM and myeloma ...
    • Renal cell carcinoma. 

      Hsieh, JJ; Purdue, MP; Signoretti, S; Swanton, C; Albiges, L; Schmidinger, M; Heng, DY; Larkin, J; Ficarra, V (2017-03-09)
      Renal cell carcinoma (RCC) denotes cancer originated from the renal epithelium and accounts for >90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, of which clear cell RCC (ccRCC) ...
    • Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. 

      Rothermundt, C; von Rappard, J; Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Rini, B; Schmidinger, M; Sternberg, CN; Putora, PM (2017-04)
      Second-line systemic treatment options for metastatic clear cell renal cell cancer (mccRCC) are diverse and treatment strategies are variable among experts. Our aim was to investigate the approach for the second-line ...